Antibodies are archetypical affinity molecules that bind specific proteins with excellent avidity. Yet the large sizes, low stabilities, and high costs of antibodies often hinder their applications. To address these limitations, the Heath lab pioneered a new class of synthetic molecules called protein catalyzed capture agents (PCC) that bind proteins like antibodies but exhibit high stabilities and can be rapidly produced at low costs. PCC technology is not only poised to disrupt antibodies, but also small molecules pharmaceuticals. Whereas conventional small molecule drugs require specific binding pockets, PCCs can bind virtually any part of a protein.
The most versatile aspect of PCCs is that they can be developed to bind virtually any protein epitope. This is achieved by using an advanced combinatorial screening method (the PCC method) that exploits non-catalyzed click chemistry to assay a combinatorial library of PCCs for high-affinity binding to a specific protein epitope. This versatility has enabled PCCs to fulfill several purposes that include drugging “undruggable” proteins in cancer (Akt1, Akt2, KRAS) and HIV, selectively detecting disease-associated biomarkers (malarial proteins, interleukin-17A/F, HIV antibodies), and in vivo imaging (VEGF and Protective Antigen protein).
Current efforts in the Heath lab focus on developing PCCs against undruggable and exploring PCCs a antibiotics against drug-resistant bacterial infections.
Protein-Catalyzed Capture Agents, Chemical Reviews (2019). Go to→
A General Synthetic Approach for Designing Epitope Targeted Macrocyclic Peptide Ligands, Angewandte Chemie International Edition (2015). Go to→
Protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH Domain of Akt1, Nature Chemistry (2015). Go to →
Allosteric Inhibitor of KRas Identified Using a Barcoded Assay Microchip Platform, Analytical Chemistry (2018). Go to→